Sanford Gips, MD
Cardiovascular Disease · Haddon Heights, NJNPI 1366493942
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,600 of the $15,415 with a category attached, or 88.2%. 44 manufacturers reported payments, led by Abbott at 26.4% of the total.
Across 599 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Philips North America LLC$1K
- AstraZeneca$1K
- Boston Scientific$1K
- Novartis$1K
- Impulse Dynamics (USA) Inc.$1K
- plus $5K from 38 others
Across 171 payments — averaging $3860.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$461K
- Novartis$140K
- Janssen Research & Development, LLC$25K
- Eli Lilly$14K
- AstraZeneca$10K
- Boehringer Ingelheim$7K
- plus $3K from 1 others
What the payments were for
- Consulting fees$8756%
- Travel & lodging$9186%
- Food & beverage$13,60088%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$1,474
- GENERAL - THERAPIES$700
- OPTIMIZER$581
- AVEIR$236
- FARXIGA$231
- VERQUVO$206
- EMBLEM$175
- UPTRAVI$149
- CardioMEMS HF System$141
- Barostim Neo System$137
- RESOLUTE ONYX$127
- ELIQUIS$113
- Ozempic$108
How this compares
$15,415 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $196,261 |
| XareltoRivaroxaban | 109 | $116,152 |
| JardianceEmpagliflozin | 78 | $102,592 |
| FarxigaDapagliflozin Propanediol | 76 | $98,262 |
| OzempicSemaglutide | 72 | $88,642 |
| EntrestoSacubitril/Valsartan | 55 | $63,158 |
| Repatha SureclickEvolocumab | 45 | $39,969 |
| MounjaroTirzepatide | 26 | $32,914 |
| BrilintaTicagrelor | 30 | $23,435 |
| Praluent PenAlirocumab | 14 | $16,161 |
| Valsartan | 304 | $10,677 |
| Metoprolol Succinate | 515 | $8,030 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 216 | $7,806 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 94 | $7,202 |
| Rosuvastatin Calcium | 330 | $5,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $361 | $196,261195 claims |
| AstraZenecaFarxiga, Brilinta | $1,211 | $121,697106 claims |
| Johnson & JohnsonXarelto | $923 | $116,152109 claims |
| Boehringer IngelheimJardiance | $476 | $102,59278 claims |
| Novo NordiskOzempic | $293 | $88,64272 claims |
| NovartisEntresto | $1,104 | $63,15855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Haddon Heights
- Dilip ViswanathHaddon Heights$167K
- Andreas PavlidesHaddon Heights$43K
- Vijayendra VermaHaddon Heights$32K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.